WebDoctor Encyclopedia

Plasma-cell neoplasms Primary bone tumours

Solitary plasmacytoma

A solitary plasmacytoma is a single tumour of abnormal plasma cells, in a bone or in soft tissue such as the nose or throat. Radiotherapy controls most, but some people later develop myeloma.

Medically reviewed Last reviewed November 15, 2026

What is a solitary plasmacytoma?

A solitary plasmacytoma is a single tumour made of abnormal plasma cells. Plasma cells are white blood cells in the bone marrow that normally make antibodies to fight infection.

In multiple myeloma, abnormal plasma cells spread throughout the bone marrow. In a solitary plasmacytoma, they form just one lump, and tests of the rest of the bone marrow and skeleton are normal or nearly normal.

There are two main types:

  • Solitary plasmacytoma of bone (SBP), which grows inside a bone, most often in the spine
  • Solitary extramedullary plasmacytoma (SEP), which grows in soft tissue outside the bone, most often in the nose, sinuses or throat

The main treatment is radiotherapy, which controls the tumour in most people. However, many people with solitary plasmacytoma of bone later develop multiple myeloma, so lifelong follow-up is needed.

1. Key facts at a glance

Feature Details
How common Rare; about 3-5% of plasma cell cancers
Typical age Median about 55-65; younger on average than people with myeloma
Sex About twice as common in men
Types Bone (about two-thirds) and extramedullary (about one-third)
Common sites Bone: spine, ribs, pelvis, skull, long bones. Extramedullary: nasal cavity, sinuses, nasopharynx, throat, tonsils
Main treatment Radiotherapy, usually 35-50 Gy
Local control Achieved in about 85-90%
Main risk Progression to multiple myeloma, more often after bone plasmacytoma

2. Causes and risk factors

The cause is unknown. Solitary plasmacytoma is not inherited and not contagious.

As in myeloma, the tumour cells come from one abnormal plasma cell that has acquired gene changes and multiplied. Many tumours make a single type of antibody or part of an antibody, which can be measured in blood or urine as a paraprotein (M-protein) or free light chains.

Factor Notes
Age Risk rises with age
Male sex Men are affected more often
Previous MGUS Some people have a known paraprotein before diagnosis

2.1 How it relates to other plasma cell conditions

Condition Plasma cells in marrow Lesions Organ damage Usual approach
MGUS Under 10% None None Monitoring only
Solitary plasmacytoma None (or under 10% with minimal involvement) One None, apart from the single lesion Radiotherapy
Smouldering myeloma 10-59% None None Monitoring or, for high-risk cases, early treatment
Multiple myeloma Usually 10% or more Often several Anaemia, kidney damage, high calcium or bone lesions Systemic treatment

This is why careful tests of the bone marrow and the whole skeleton are needed before the diagnosis of solitary plasmacytoma can be made.

3. How does it look?

3.1 On the body

Site What may be seen or felt
Spine Usually nothing visible; pain or loss of height if a vertebra collapses
Rib, skull or long bone A hard swelling over the bone in some cases
Nose and sinuses A soft, red or purple fleshy mass inside the nose, sometimes bleeding easily
Throat and tonsils A smooth, round swelling at the back of the throat or on a tonsil
Neck Enlarged lymph nodes in some extramedullary cases

3.2 On scans

Test Typical finding
X-ray A single lytic (punched-out) area in the bone, sometimes with expansion of the bone or a fracture
MRI A soft-tissue mass in or around the bone; essential for spinal tumours to check for pressure on the spinal cord
PET-CT A single area of high activity; also looks for hidden lesions elsewhere
CT of head and neck Shows the size of extramedullary tumours in the nose or throat

3.3 Under the microscope

Feature Description
Cells Sheets of plasma cells, from mature-looking to more immature forms
Markers Positive for CD138 and CD38; usually negative for CD19 and CD45; often CD56 positive
Clonality All cells make the same light chain (kappa or lambda only)

4. Symptoms

Type Common symptoms
Bone plasmacytoma Bone pain at one site, often the back; a fracture after minor injury; a lump over a bone
Spinal plasmacytoma Back pain; if the spinal cord or nerves are compressed: leg weakness, numbness, tingling, or problems controlling bladder or bowels
Extramedullary in the nose and sinuses Blocked nose, nosebleeds, nasal discharge, facial swelling or pain
Extramedullary in the throat Sore throat, difficulty swallowing, hoarse voice, snoring or a lump in the neck
Other extramedullary sites Depends on the site, such as the gut, lung, skin or lymph nodes

Unlike multiple myeloma, solitary plasmacytoma does not usually cause anaemia, kidney damage or high calcium.

4.1 Emergency symptoms

Spinal cord compression is an emergency. Seek urgent help for:

5. Diagnosis

Diagnosis follows the criteria of the International Myeloma Working Group (IMWG):

Requirement Details
Biopsy Proven single lesion of clonal plasma cells in bone or soft tissue
Bone marrow No clonal plasma cells in a random marrow sample (or fewer than 10% in “solitary plasmacytoma with minimal marrow involvement”)
Imaging No other lesions on whole-body MRI, PET-CT or low-dose CT, apart from the main tumour
No myeloma-related organ damage No anaemia, high calcium or kidney damage due to plasma cells (the “CRAB” features)

5.1 Tests used

Test Purpose
Biopsy of the lesion Confirms plasmacytoma
Bone marrow biopsy with flow cytometry Looks for hidden abnormal plasma cells; even small amounts raise the risk of myeloma
Serum and urine protein electrophoresis Detects and measures any paraprotein
Serum free light chains Measures kappa and lambda light chains
Blood count, calcium, kidney function Excludes myeloma-related damage
Whole-body PET-CT or MRI Excludes other lesions

6. Treatment

6.1 Radiotherapy

Radiotherapy is the standard treatment for both types. International Lymphoma Radiation Oncology Group (ILROG) guidelines recommend:

Situation Typical dose
Extramedullary plasmacytoma About 40-50 Gy; nearby lymph nodes may be included for head and neck tumours
Bone plasmacytoma under 5 cm About 35-40 Gy
Bone plasmacytoma 5 cm or larger About 40-50 Gy

Treatment is usually given on weekdays over about 4-5 weeks. Each session takes only a few minutes.

6.2 Surgery

Situation Role of surgery
Unstable spine or fracture Stabilisation surgery, followed by radiotherapy
Spinal cord compression Urgent surgery and/or radiotherapy, with steroids
Small extramedullary tumour Sometimes removed completely, then radiotherapy may be given

6.3 Systemic treatment

Situation Approach
Standard solitary plasmacytoma Chemotherapy is not routinely given after radiotherapy
Large tumours, high-risk features, or tumour not controlled Myeloma-type treatment may be considered, ideally in a trial
Progression to multiple myeloma Treated as myeloma

6.4 Side effects of radiotherapy

Site Possible side effects
Spine or chest Tiredness, sore throat or gullet, nausea, skin redness
Nose, sinuses or throat Dry or sore mouth, taste changes, nasal crusting, dry eyes; later dry mouth and dental problems
Pelvis Bowel or bladder irritation, lower blood counts

6.5 Response after treatment

Doctors judge response using imaging and blood tests, following European expert recommendations:

Measure What it shows
Paraprotein and free light chains Often fall slowly over months; complete disappearance is a good sign
MRI or PET-CT at 6-12 months Reduced activity or size of the lesion; the bone may never look completely normal
Persistent paraprotein Raises the risk of later myeloma and calls for closer follow-up
New lesions May mean the disease has become myeloma and needs further tests

Healing of the bone can take a long time. A remaining shadow on a scan does not always mean active disease.

7. Outlook (prognosis)

Measure Approximate figure
Local control after radiotherapy About 85-90%
Progression to myeloma: bone plasmacytoma About half within 10 years
Progression to myeloma: extramedullary plasmacytoma Lower, roughly 10-30%
Minimal marrow involvement on flow cytometry Much higher risk of progression
Overall survival Median around 10 years or more, longer for extramedullary plasmacytoma

Factors linked to a higher risk of progression include:

Factor Notes
Bone (rather than extramedullary) site Main risk factor
Clonal plasma cells in the bone marrow Even small amounts
Abnormal free light chain ratio At diagnosis
Paraprotein persisting after radiotherapy Especially if it stays at the same level for over a year
Tumour size 5 cm or larger In some studies

8. Follow-up

What How often
Blood tests (paraprotein, free light chains, blood count, calcium, kidney function) Every 3-6 months for at least 5 years, then yearly
Imaging (MRI or PET-CT) About 6-12 months after radiotherapy to check response, then if symptoms or blood tests change
Length of follow-up Lifelong, because myeloma can develop many years later

Report new bone pain, tiredness, frequent infections, thirst, or new lumps to your team.

9. Living with solitary plasmacytoma

Topic Practical advice
After spinal radiotherapy Pain usually improves over weeks; a physiotherapist can advise on safe lifting and exercise
Bone health Weight-bearing exercise, calcium and vitamin D help; your team may check bone density
Dental care After head and neck radiotherapy, regular dental checks and fluoride help protect teeth
Work and travel Most people return to normal activities after treatment
Mental wellbeing Uncertainty about myeloma can cause anxiety; regular follow-up and open discussion with your team help

10. Frequently asked questions

Question Answer
Is a solitary plasmacytoma cancer? Yes. It is a cancer of plasma cells, but limited to one place and often controlled with radiotherapy
Is it the same as multiple myeloma? No, but the two are closely related. Some people later develop myeloma
Will I need chemotherapy? Usually not, unless the disease progresses to myeloma
Can it be cured? Radiotherapy can cure many people, particularly with extramedullary plasmacytoma
Why do I need blood tests for so long? To detect early signs of myeloma, which can then be treated promptly
What happens if myeloma develops? It is usually found early through blood tests and treated with modern myeloma drugs, which control the disease for many years in most people
Can it come back in the same place? Uncommonly. Radiotherapy controls the original tumour in about 9 in 10 people

Resources

  1. Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
  2. Rajkumar, S.V. et al. (2014) ‘International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma’, The Lancet Oncology, 15(12), pp. e538-e548.
  3. Caers, J. et al. (2018) ‘Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel’, Journal of Hematology and Oncology, 11(1), 10.
  4. Soutar, R. et al. (2004) ‘Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma’, British Journal of Haematology, 124(6), pp. 717-726.
  5. Tsang, R.W. et al. (2018) ‘Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group’, International Journal of Radiation Oncology, Biology, Physics, 101(4), pp. 794-808.
  6. Dores, G.M. et al. (2009) ‘Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004’, British Journal of Haematology, 144(1), pp. 86-94.
  7. Dimopoulos, M.A., Moulopoulos, L.A., Maniatis, A. and Alexanian, R. (2000) ‘Solitary plasmacytoma of bone and asymptomatic multiple myeloma’, Blood, 96(6), pp. 2037-2044.
  8. Ozsahin, M. et al. (2006) ‘Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients’, International Journal of Radiation Oncology, Biology, Physics, 64(1), pp. 210-217.
  9. Knobel, D. et al. (2006) ‘Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study’, BMC Cancer, 6, 118.
  10. Paiva, B. et al. (2014) ‘Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma’, Blood, 124(8), pp. 1300-1303.
  11. Hill, Q.A. et al. (2014) ‘Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis’, Blood, 124(8), pp. 1296-1299.
  12. Nahi, H. et al. (2017) ‘Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register’, European Journal of Haematology, 99(3), pp. 216-222.
  13. Charalampous, C. et al. (2025) ‘Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes’, Blood Advances, 9(7), pp. 1559-1570.
  14. National Cancer Institute (2026) Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ) – Patient Version. Available at: https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.